Cabaletta Bio, Inc.
Cabaletta Bio, Inc. (NASDAQ: CABA) is a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies designed to provide deep and durable responses for patients with autoimmune diseases. The company's website is www.cabalettabio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cabaletta Bio, Inc. does
In the company’s own words
Cabaletta Bio, Inc. (NASDAQ: CABA) is a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies designed to provide deep and durable responses for patients with autoimmune diseases. The company's website is www.cabalettabio.com.
The company's proprietary CABA platform, which stands for Cabaletta Approach to B cell Ablation, focuses on the CARTA approach—Chimeric Antigen Receptor T cells for Autoimmunity—designed to potentially reset the immune system. Resecabtagene autoleucel, or rese-cel, is the company's lead product candidate, a fully human CD19-CAR T construct engineered to achieve transient and deep depletion of all B cells following a single infusion. The construct is designed to eliminate disease-causing B cells while allowing healthy transitional and naive B cells to repopulate, thereby restoring normal immune function.
Cabaletta is advancing five Phase 1/2 clinical trials under the RESET program evaluating rese-cel across multiple autoimmune indications including systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. In December 2025, the company initiated a registrational trial for patients with dermatomyositis and anti-synthetase syndrome. The company has received FDA Fast Track Designation for rese-cel in multiple indications and Regenerative Medicine Advanced Therapy designation for myositis and lupus nephritis.
The company's manufacturing strategy utilizes multiple contract development and manufacturing organizations including Oxford Biomedica, Minaris Advanced Therapies, Lonza Houston, and Cellares Corporation. In January 2026, the company announced IND clearance for rese-cel manufactured using Cellares' automated Cell Shuttle platform, which offers potential scalability to produce rese-cel for thousands of patients annually with minimal capital investment.
Cabaletta was founded in 2017 by scientific co-founders from the University of Pennsylvania who combined expertise in B cell-mediated autoimmune diseases with deep knowledge of CAR T therapy development. The company is a clinical-stage organization with limited operating history that has incurred significant losses since inception and anticipates continued losses for the foreseeable future. The company identified conditions raising substantial doubt about its ability to continue as a going concern without securing additional funding beyond its current cash position.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1759138
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cabaletta Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cabaletta Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cabaletta Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cabaletta Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cabaletta Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”